Microbiome Characterization System for Autoimmune Diagnostics

The patent segments the microbiome analysis system into distinct functional modules: sample processing units, genetic analysis units, data processing units, and therapeutic recommendation units. This segmentation allows the system to handle individualized analysis with high precision while managing complexity through modular architecture, where each module performs a specific function in the diagnostic workflow.

The patent transitions from traditional population-level aggregate analysis to multi-dimensional individualized analysis by incorporating subject-specific metadata (demographics, clinical history, lifestyle factors) alongside microbiome data. This dimensional expansion enables precise individualized diagnostics while the systematic integration of multiple data types provides a structured framework to manage the increased complexity.

The patent implements preliminary action by pre-processing and normalizing microbiome data during sample collection and initial analysis phases. Reference databases and analytical algorithms are prepared in advance, allowing comprehensive microbiome characterization to be performed efficiently when clinical samples are received, thus maintaining high prediction accuracy while reducing actual processing time for patient diagnoses.

The patent uses copying by creating virtual representations of microbiome communities through computational models and reference databases. Instead of performing exhaustive physical analysis of every sample from scratch, the system compares patient microbiome profiles against stored reference copies and models, enabling accurate disease prediction with reduced processing time and resource requirements.

The patent applies parameter changes by systematically varying key parameters in probiotic and phage formulations based on individual patient microbiome profiles. The system adjusts bacterial strain compositions, phage concentrations, and delivery vehicle parameters to match each patient's specific microbial ecosystem, achieving high therapeutic precision while using standardized manufacturing processes that can accommodate parameter variations efficiently.

The patent implements universality by developing a platform technology that can generate multiple tailored therapies from a core set of proven microbial strains and phages. The same diagnostic and formulation platform serves multiple therapeutic indications (autoimmune diseases, metabolic disorders, gastrointestinal conditions), and the manufacturing system can produce different customized formulations using common production lines and delivery mechanisms, reducing overall manufacturing complexity.